SCHEMBL1029630

SCHEMBL1029630

CC(C)(C)OC(=O)N1[C@@H]2CC[C@H]1C[C@H](OS(C)(=O)=O)C2

nearest known ligand 0.67

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.67
CHRM1 P11229 1/20 0.67
CHRM3 P20309 1/20 0.67
PREP P48147 4/20 0.46
HSD11B1 P28845 1/20 0.45
GPR119 Q8TDV5 13/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19082744 1.00 CHRM2 (0.67) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL660057 1.00 CHRM2 (0.67) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL1027350 1.00 CHRM2 (0.67) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL26970792 1.00 CHRM2 (0.67) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL18662292 1.00 CHRM2 (0.67) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL18682177 1.00 CHRM2 (0.67) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL30128274 1.00 CHRM2 (0.67) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL16421281 1.00 CHRM2 (0.67) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL20635018 1.00 CHRM2 (0.67) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL911107 0.94 CHRM2 (0.59) CHRM2CHRM1CHRM3PREPHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230037255-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2023-02-02 US disclosed
EP-3661925-B1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2021-11-24 EP disclosed
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-04-01 US disclosed
US-20200291003-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS SYGNATURE DISCOVERY LIMITED (GB) 2020-09-17 US disclosed
US-10336719-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-07-02 US disclosed
WO-2019008025-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-01-10 WO disclosed
US-20170305857-A1 N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (UK) 2017-10-26 US disclosed
US-20170305857-A1 N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (UK) 2017-10-26 US disclosed
US-20170190681-A1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS Glaxosmithline Intellectual Property Development Limited (GB) 2017-07-06 US disclosed
US-9694002-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2017-07-04 US disclosed
US-8163898-B2 4-sulfonylpiperidine derivatives MSD K. K. (JP) 2012-04-24 US disclosed
WO-2011059021-A1 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2011-05-19 WO disclosed
WO-2011021645-A1 BICYCLIC UREA DERIVATIVE OR PHARMACOLOGICALLY PERMITTED SALT THEREOF 大日本住友製薬株式会社 (JP) 2011-02-24 WO disclosed
EP-1957493-B1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS ORGANON NV (NL) 2011-01-19 EP disclosed
US-20100234392-A1 4-SULFONYLPIPERIDINE DERIVATIVES MSD K.K. (JP) 2010-09-16 US disclosed
EP-2204368-A1 4-SULFONYLPIPERIDINE DERIVATIVES Banyu Pharmaceutical Co., Ltd. (JP) 2010-07-07 EP disclosed
US-7605170-B2 8-azabicyclo[3.2.1]octane derivatives N.V. ORGANON (NL) 2009-10-20 US disclosed
EP-1957493-A1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS N.V. Organon (NL) 2008-08-20 EP disclosed
US-20070185156-A1 8-Azabicyclo[3.2.1]octane derivatives N.V. ORGANON (NL) 2007-08-09 US disclosed
WO-2007063071-A1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS N.V. ORGANON (NL) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190681-A1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS CXCR2, CXCR1, CXCR3 CHRM2 3706/4885CHRM1 3744/4885CHRM3 2833/4885
US-20170305857-A1 N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS TNNI3, MUSK, MYLK2 CHRM2 2559/4885CHRM1 2299/4885CHRM3 1596/4885
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SULT2A1 CHRM2 439/4885CHRM1 665/4885CHRM3 824/4885
US-10336719-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors CXCR2, CXCR1, CXCR3 CHRM2 3586/4885CHRM1 3544/4885CHRM3 2829/4885
US-20200291003-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 CHRM2 1374/4885CHRM1 1202/4885CHRM3 1494/4885
US-20230037255-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 CHRM2 1267/4885CHRM1 1101/4885CHRM3 1411/4885
US-20100234392-A1 4-SULFONYLPIPERIDINE DERIVATIVES CHRM2, CHRM1, CHRM3 CHRM2 1/4885CHRM1 2/4885CHRM3 3/4885
US-20070185156-A1 8-Azabicyclo[3.2.1]octane derivatives SLC22A8, SLCO1B3, SLCO1B1 CHRM2 1718/4885CHRM1 1961/4885CHRM3 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.